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Abstract
Loss of vascular barrier function causes leak of fluid and proteins into tissues, extensive leak leads to shock and death.
Barriers are largely formed by endothelial cell-cell contacts built up by VE-cadherin and are under the control of
RhoGTPases. Here we show that a natural plasmin digest product of fibrin, peptide Bß15-42 (also called FX06), significantly
reduces vascular leak and mortality in animal models for Dengue shock syndrome. The ability of Bß15-42 to preserve
endothelial barriers is confirmed in rats i.v.-injected with LPS. In endothelial cells, Bß15-42 prevents thrombin-induced stress
fiber formation, myosin light chain phosphorylation and RhoA activation. The molecular key for the protective effect of
Bß15-42 is the src kinase Fyn, which associates with VE-cadherin-containing junctions. Following exposure to Bß15-42 Fyn
dissociates from VE-cadherin and associates with p190RhoGAP, a known antagonists of RhoA activation. The role of Fyn in
transducing effects of Bß15-42 is confirmed in Fyn
2/2 mice, where the peptide is unable to reduce LPS-induced lung
edema, whereas in wild type littermates the peptide significantly reduces leak. Our results demonstrate a novel function for
Bß15-42. Formerly mainly considered as a degradation product occurring after fibrin inactivation, it has now to be
considered as a signaling molecule. It stabilizes endothelial barriers and thus could be an attractive adjuvant in the
treatment of shock.
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Introduction
Capillary leak may be transient, as seen in response to histamine
or prolonged as seen in response to thrombin [1]. Extensive
leakage often occurs in intensive care patients and is thought to be
caused by the exposure of endothelial cells to activated coagulation
factors (e.g., thrombin) plus pro-inflammatory stimuli (VEGF,
LPS, and others). This results in endothelial cell activation,
downregulation of thrombin inhibitors and activation of the small
GTPase RhoA. [2–6]. By regulating levels of myosin light chain
phosphorylation and actin stress fiber formation RhoA controls
cell contraction [1,7–9]. Moreover, it results in a rapid activation
and redistribution of the integrin-associated focal adhesion kinase
(FAK) to the tips of stress fibers [10] thereby giving anchorage
support for cell contraction [11]. Cell contraction and rupture of
cell-cell contacts results in gap formation and leak [7,12–14]. VE-
cadherin is directly connected to the actin-based cytoskeleton and
is one of the key molecules integrating signals for opening and
tightening of cell junctions [15–17].
Peptide Bb15-42 interacts with VE-cadherin [4,18,19]. Bb15-42 is
a 28 amino acid cleavage product of fibrin. Following thrombin-
induced fibrin formation it is released from fibrin E1 fragments by
the action of plasmin and represents a sensitive indicator of
fibrinolytic activity [20]. This peptide, also called FX06, was
shown to prevent myocardial reperfusion injury and to reduce
infarct sizes in animal models for myocardial ischemia/reperfusion
[4,20,21]. Also in a multi-centre phase IIa clinical trial FX06
significantly reduced the size of the necrotic core of infarcts in
patients with acute myocardial infarction undergoing primary
percutaneous coronary intervention [22].
Parts of this beneficial effect may be explained by the anti-
inflammatory properties of FX06 [4]. With VE-cadherin being the
molecular target of FX06 we wished to test the hypothesis that this
peptide is also interfering with endothelial barrier function. We
therefore selected two different models for capillary leak. First, we
used an animal model for Dengue shock syndrome (DSS) [23].
DSS -as a hallmark of the disease- presents with slowly progressive
vascular leakage developing within days ultimately leading to
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5391death [24,25]. Second, we used a LPS-induced shock model,
which rapidly develops leakage within hours [26]. Here we show
that FX06 prevents stress-induced RhoA activation. It preserves
endothelial barrier function in DSS or LPS-induced shock
improves clinical outcomes. As a molecular key for the protective
effect of FX06 we identified the src kinase Fyn.
Results
FX06 improved survival and reduced capillary leak in
Dengue-induced shock
Dengue shock syndrome (DSS) in humans is characterized by
progressive capillary leak [24,25]. This progressive loss of vascular
barrier function is mimicked in our mouse model. Following
Dengue infection i.p., mice developed arching backs, ruffling fur,
slowed activity, and finally, at days 5–9, they died in a dose-
dependent fashion (Fig. 1A). As seen in human patients with DSS
[27], our mice presented hemoconcentration and fibrinogen
consumption (Fig. 1C) and progressive capillary leak within lungs
and the intestine (Fig. 1D). Of not, survival rates correlate with
viral titers, which also correlates to the human situation where
disease severity correlates with viral loads [28].
Animals treated with FX06 (first treatment on day 3 post
infection) had significantly improved survival rates (Fig. 1A),
significantly reduced capillary leak within lungs and the intestine
(Fig. 1D) and significantly reduced hemoconcentration and
fibrinogen consumption (Fig. 1C). Virus loads in serum, liver
and brains peaked at day 7 and did not differ between groups
(Fig. 1B).
FX06 reduced capillary leak in systemic LPS shock
To further substantiate the finding that FX06 reduced capillary
leak, we injected rats with the gram negative toxin LPS i.v..
Capillary leak was assessed by quantifying extravasated 1 mm-
seized FluoSpheresH within lungs of LPS-exposed animals. Fluo-
SpheresH within lungs were qualitatively analyzed by histology
(example shown in Fig. 2A+B), which was indicative for a
reduction of beads in FX06-treated rats (Fig 2B). For quantitative
evaluation, FluoSpheresH were recovered from the entire left lungs
in each animal by tissue homogenization. Retained fluorescence/g
tissue was significantly reduced in FX06-treated animals (Fig. 2C).
Further evaluation of organ damage revealed elevated serum liver
transaminases in LPS-injected rats (AST mean 1013+/21016
U/l; ALT mean 649+/2835 U/l), which were significantly
reduced by FX06 treatment (451+/2202 U/l and 230+/
2215 U/l, respectively; n=10/group; p,0.05). Plasma fibrino-
gen was 139+/226 mg/dl in sham treated animals, 44+/216 in
LPS-treated and 54+/220 mg/dl in LPS+FX06-treated animals.
FX06 reduced thrombin-induced stress fiber formation
Both dengue and LPS models demonstrated fibrinogen
consumption indicative for thrombin activation. Thrombin is
known to activate the contractile apparatus of endothelial cells
resulting in barrier dysfunction [9,11,29]. We therefore first tested
effects of the peptide on thrombin-induced stress fiber formation.
As shown in Fig. 3A, thrombin induced pronounced parallel
bundling of actin fibers (stress fiber formation), increased
phosphorylation of myosin light chain and disrupted the
continuous lining of VE-cadherin at endothelial surfaces.
In the presence of thrombin plus FX06 only a few stress fibers
pervaded the cell. Filamentous actin was mainly located at the
cortical band, phosphorylated myosin light chain (pMLC) was
found at endothelial cross points and VE-cadherin formed a
continuous lining (similar to controls, Fig. 3A). Stress responses
were scored (see Methods) and FX06 reduced median thrombin-
induced scores by 50% (p,0.05, Figure 3B). The peptide alone
had no effect on stress fiber formation and phosphorylation of
myosin light chain. Random peptide [4] used as an additional
control showed identical results as medium control.
FX06 inhibited thrombin-induced Focal Adhesion Kinase
(FAK) redistribution
It is well documented that for efficient thrombin-induced cell
contraction the activation of focal adhesion kinase (FAK) is
required. This provides anchorage to the matrix to allow
coordinated cell contraction [11,30]. As expected [10], we found
that thrombin induced a redistribution of pFAK to the tips of stress
fibers (Fig. 4A and B). In contrast, in cells treated with thrombin in
the presence of FX06, pFAK remained diffusely distributed in the
cytosol comparable to controls (Fig. 4A).
FX06 reduced thrombin-induced RhoA activation
Stress fiber formation and myosin light chain activation is under
the control of the counteractive balance between RhoA and Rac1
[8,31–34]. As well documented [9], we found thrombin to
augment active RhoA and to reduce active Rac1 as determined
in pull down assays using GST-coupled Rhotekin and GST-
coupled Pak-1 as binding partners for activated GTPases (Fig. 5).
Treatment with FX06 alone had reverse effects; it activated Rac1
and decreased the amount of active RhoA (Fig. 5). Combining
thrombin with FX06 completely blocked thrombin-induced RhoA
activation (Fig. 5).
FX06 dissociated Fyn from VE-cadherin
The only yet known endothelial binding partner of the Bß15-42
sequence of FX06 is VE-cadherin [4,18,19], which has been
described to interfere with the counteractive balance of RhoA and
Rac1; VE-cadherin/VE-cadherin engagement reduces RhoA and
induces Rac1 activity [34,35]. Since functions of VE-cadherin
largely depend on its cytosolic binding partners, we screened
effects of the peptide on the composition of the VE-cadherin
complex (catenins, VE-PTP, p120cat, c-src, csk and Fyn; data
shown for Fyn only). The only significant change observed with
FX06 was a rapid dissociation of the src kinase Fyn from VE-
cadherin (Fig. 6A). This was paralleled by association of Fyn with
FAK with p190RhoGAP (Fig. 6B). Interestingly, thrombin had no
effect on the VE-cadherin/Fyn association, whereas the combi-
nation of thrombin+FX06 dissociated Fyn from VE-cadherin
(Fig. 6A) and associated Fyn with p190RhoGAP (Fig. 6B–D). This
raised the possibility that FX06 protected cells from thrombin-
induced cell activation in a Fyn-dependent fashion. We tested this
in endothelial cells treated with Fyn shRNA which still responded
to thrombin, but FX06 was unable to prevent stress fiber
formation (Figure S1).
LPS pneumonitis model with wild-type and Fyn
2/2 mice
As a proof of concept, we tested effects of FX06 in a mouse
model of pneumonitis using wild-type and Fyn
2/2 mice.
Intranasal administration of LPS induced pulmonary inflamma-
tion as determined by myeloperoxidase (MPO) activity in lung
lysates (4753+/21018 pg/ml lung). Moreover, LPS induced
capillary leak as determined by Evan’s blue accumulation within
lungs as compared to sham-treated animals. Leak (Fig. 7) and
inflammation (3050+/2115 pg/ml lung) were significantly dimin-
ished in FX06-treated animals. In contrast, no peptide-related
reduction of leak (Fig. 7) or reduction of inflammation (4329+/
21417 and 4157+/21091 pg/ml respectively) was observed in
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PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5391Figure 1. FX06 improved survival following dengue-infection. A. Dengue virus was inoculated i.p. at day 0. Starting with day 3, animals were
treated with NaCl (100 ml) or indicated doses of FX06 (diluted in 100 ml NaCl). In 16LD50 and 26LD50 groups, differences in survival rates between
the NaCl and the FX06 groups were significant (p,0.05). B. Virus titers following Dengue infection. Mice were infected with 26LD50 of Dengue virus
i.p and treated with NaCl (controls) or FX06 (2.4 mg/kg bodyweight twice daily). The virus load was quantified by titration of serum or brain lysates
onto Vero E6 cell cultures as described Diamond [51] and plaque forming units (PFU) per ml serum or per mg organ were determined. n=3/data
point. All control treated animals were dead at day 9. C. Hematocrit and fibrinogen following Dengue infection. Mice were infected with 26LD50 of
Dengue virus i.p and treated with NaCl (controls) or FX06 (2.4 mg/kg bodyweight twice daily). n=3/data point, all control mice were dead at day 9, *
denotes p,0.05 as compared with controls. D. Organs of 15 animals per time point and group infected with 26LD50 were analyzed. Treatment
started at day 3, mice received NaCl or FX06 (daily dose was 4.8 mg/kg bodyweight in 100 ml NaCl i.p.). Samples at day 3 were taken before treatment
was initiated. Evan’s blue extravasation was measured as described in Methods and data are presented as optical density above that of healthy
controls. At days 5 and 7, in lungs and the intestine, the difference in Evan’s blue extravasation between the NaCl and the FX06 group was significant
(*p,0.05, mean+/2SD).
doi:10.1371/journal.pone.0005391.g001
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2/2 mice confirming the role of Fyn in mediating protective
effects of FX06.
Discussion
Data demonstrate that FX06, a plasmin cleavage product of
fibrin, reduces capillary leak during sepsis or lung injury. We have
shown this in three models of capillary leak. First, the Dengue
shock model, where capillary leak started at day 3 and is slowly
progressive thereafter and reaches a maximum at day 7. In this
model FX06 significantly reduced leak as determined by Evan’s
blue extravasation and improved survival. Second, we used an
intravenous LPS shock model in rats. Importantly, in this non-
recovery model barrier function was measured by extravasation of
1 mm-sized beads, which do not extravasate in subacute models
like Dengue. Even in this most severe model for a loss of
endothelial barrier function FX06 was able to reduce leakage.
Third, we used a pneumonitis model induced by LPS inhalation,
where FX06 reduced pulmonary leak.
We have shown previously that FX06 forms low affinity
interactions with VE-cadherin and has anti-inflammatory proper-
ties [4]. We proposed a model where fibrin E1 fragment binding to
endothelial VE-cadherin resulted in leukocyte transmigration. The
concomitant presence of the fibrin fragment Bbeta15-42 (here
called FX06) competed with E1 framents for binding to VE-
cadherin thereby reduced leukocyte transmigration. Here we show
that FX06 is also a signaling molecule. It antagonizes RhoA
activation in vitro and reduces vascular leak in vivo. As reviewed
recently by Vestweber [17] mechanisms of leukocyte transmigra-
tion and vascular permeability are tightly linked and strongly
influenced by VE-cadherin functions. VE-cadherin is a trans-
membrane molecule crucially involved in the regulation of
endothelial barrier function and RhoA activity [16,35,36]. FAK
reorganisation, actin stress fiber formation and RhoA activation
are established signs of stress-induced vascular hyperpermeability
[6,9,37,38].
VE-cadherin is organized in a multimeric protein complex
called adherens junction. Both, the phosphorylation status of VE-
cadherin and the composition of this protein complex are altered
in response to factors interfering with vascular barrier function.
Among proteins known to be associated with cadherins are
catenins, VE-PTP, p120cat, c-src, csk or Fyn. Thus, in a next step
we analyzed whether FX06 altered the composition of the VE-
cadherin complex. Among proteins co-precipitated with VE-
cadherin, only Fyn was significantly affected. The addition of
FX06 to endothelial cells caused an immediate dissociation of Fyn
from VE-cadherin.
Fyn is a broadly expressed regulatory src kinase. Fyn knock-out
mice are viable and have no apparent phenotype [37,39–41], most
likely due to compensation by other src kinase family proteins [42].
Also overexpression of Fyn has little effects on the phosphorylation
status of other proteins [43,44]. Not much is known about the
function of Fyn in endothelial cells with one exception, the anti-
angiogenic effect of thrombospondin requires Fyn [45]. Fyn has
been shown to associate with FAK [40,43,46] and p190RhoGAP
[35,47]. We here show that Fyn associates with the VE-cadherin-
containing adhesion complex and that FX06 dissociates Fyn from
VE-cadherin and associates Fyn to p190RhoGAP, known to
Figure 2. FX06 decreased capillary leak following LPS injection
in rats. One hour after LPS injection (i.v., 12 mg/kg), FX06 (2.4 mg/kg)
or an equal volume of NaCl (100 ml) were injected i.v.; 350 min after LPS
injection, FluoSpheresH were injected i.v.; 360 min. after LPS injection,
rats were sacrificed. The right lung was used for histology and
photographed on a laser scan microscope. Examples of images from
LPS (A) or LPS+FX06-treated animals (B). From the entire left lung,
FluoSpheresH were recovered and fluorescence measured by ELISA as
described in Methods (C). The difference between LPS and LPS plus
FX06 was significant (n=11 per group; * denotes p,0.05, mean+/2SD).
doi:10.1371/journal.pone.0005391.g002
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maintaining endothelial barrier function [48]. In this context it is
of note that FX06 also prevented redistribution of FAK to the tips
of stress fibers. It is well documented that for efficient cell
contraction FAK is required. FAK provides anchorage to the
matrix to allow coordinated cell contraction [11,30]. Thus,
inhibition of FAK relocation might also contribute to the ability
of FX06 to maintain barrier function. Anyway, our immunopre-
cipitation studies postulated that Fyn is a switchpoint for mediating
effects of FX06 on endothelial barrier function. To prove this
assumption, we used Fyn
2/2 mice in a pneumonitis model, where
LPS induced capillary leak in both, wild-type and knock-out mice,
but the protective effect of FX06 was seen in wild-type animals
only. We have confirmed the role of Fyn cell culture. FX06 was
unable to prevent stress fiber formation in cells infected with Fyn
shRNA.
Of note, FX06 also reduced pulmonary inflammation in wild
type mice. Given our primary hypothesis that FX06 prevents
inflammation by competing with fibrin E1 fragments for the
binding to VE-cadherin, we expected that FX06 would diminish
inflammation also in Fyn2/2 mice also. However, this was not
the case. At this point there is no clear answer to this issue, but it
can be assumed that inflammatory cells require both, the adhesive
step as well as the opening signal to VE-cadherin-based junctions
to transmigrate into tissues [17]. In case of FX06, the hierarchy of
events (competition with E1 fragments or signaling through Fyn)
that prevent inflammation is not established.
There is an interesting analogy between the effects of FX06 on
cadherin-based junctions and the physiological effect of homotypic
VE-cadherin/VE-cadherin engagement: both results in a reduc-
tion of activated RhoA. In the case of cadherin engagement, this is
mediated by a yet not identified src kinase family member [35], in
case of FX06, this depends on Fyn. In conclusion, we show that
FX06 is a signaling molecule that stabilizes endothelial barriers.
Combined with the previously described anti-inflammatory effects
of FX06 [4], this peptide appears as an attractive adjuvant in the
treatment of inflammatory disorders associated with a break down
of vascular barrier function.
Methods
Ethics statement
All procedures were carried out in accordance with the Guide for
the Care and Use of Laboratory Animals (NIH Publication No. 86-23).
All experiments were approved by local committees and regional
governments on animal experimentation: ‘‘Vector’’ Bioethical
Committee (IACUC A5505-01), Russia; Medical University
Vienna and Vienna government (MA58).
Peptides and Proteins
FX06 (Bb15-42; GHRPLDKKREEAPSLRPAPPPISGGGYR,
3039.4D) and random peptide (DRGAPAHRPP RGPISGRSTP
EKEKLLPG [4]) were produced by solid-phase peptide synthesis
and purified with reversed-phase high performance liquid
chromatography using nucleosil 100-10C18 columns (Lonza,
Brussels and piChem Forschungs- und Entwicklungs-GmbH,
Graz). Thrombin (human) was from Sigma-Aldrich.
Animal models
Dengue virus infection. Experiments were performed in the
BSL-3 facility (SRC VB ‘Vector’, Russia. The dengue virus DEN-
2 (strain P23085) was adapted to adult BALB/c mice (haplotype
H-2d) by numbers of sequential intracerebral (i.c.) through suckling
BALB/c mice followed by intraperitoneal (i.p.) passages through
immune competent mice at different ages as described [23];
GenBank #AY927231. Six week old male BALB/c mice (14–
16 g) infected with this virus i.p. develop fever, thrombocytopenia,
hemoconcentration and virus-induced death in a dose-dependent
fashion [23,49]. Treatment with FX06 or NaCl was initiated at
day 3 following virus infection (i.p.). The daily doses were split into
two halves, one injected i.p in the morning the other in the
evening. Mice were monitored for signs of morbidity and mortality
at least twice daily until day 21. Under methoxyflurane
anaesthesia blood was taken from the orbital sinus. Capillary
leak was determined at days 3, 5 and 7 by i.v. injection of 200 mlo f
2% Evan’s blue in NaCl. One hour later mice were anesthetized
and then perfused with 5 ml PBS through the left cardiac
ventricle. Organs were removed and Evan’s Blue extravasation
was quantified as described [50]. Briefly, following tissue
homogenization, centrifugation at 5000 g for 30 min,
supernatants were analyzed for absorbance at 620 nm. For
comparison, Evan’s blue was injected into age matched mice
neither infected with dengue nor injected with FX06. Leak was
calculated as OD values above that of healthy controls.
The virus load was quantified by titration of serum or brain
lysates onto Vero E6 cell cultures as described Diamond [51] and
plaque forming units (PFU) per ml serum or per mg organ were
determined.
Lipopolysaccaride shock. Male Spraque Dawley rats (250–
280 g; Himberg, Austria) were anesthetized with 100 mg/kg
sodium thiopentone (Sandoz). Body temperature was kept
constant with a homoeothermic blanket. The trachea and the
right jugular vein were cannulated. Following fluid replacement
(500 ml 0.9% saline i.v.) animals were allowed to stabilize for
15 min. Then, 12 mg/kg LPS (E. coli serotype 0.127:B8; Sigma-
Aldrich) was injected i.v. One hour later, 2.4 mg/kg FX06 or
NaCl were injected i.v. as a bolus. 350 min after LPS injection,
each rat received FluoSpheresH polystyrene microspheres, 1.0 mm,
yellow-green fluorescent i.v. (1.2610
8/kg bodyweight), labeled
with a yellow-green fluorescent dye (Invitrogen Molecular Probes).
Six hours after LPS injection, rats were sacrificed and lungs
removed. From the left lung, FluoSpheresH were recovered by
washing, digestion in KOH and subsequent fluorescent dye
extraction according to manufacturer instructions. Fluorescence
was determined at Ex 485/Em 538 nm. The right lung was fixed
in 4% paraformaldehyde, dehydrated in ascending alcohol
concentrations (w/o using xylol) and embedded in paraplast.
Figure 3. FX06 prevented thrombin-induced actin-bundling and myosin light chain phosphorylation (pMLC). A. Examples of laser scan
images of an immunofluorescence triple staining: actin (left) pMLC (middle), and VE-cadherin (right column). Endothelial cells were exposed to
thrombin (1 U/ml), FX06 (50 mg/ml) or thrombin+FX06 for 5 min. Following thrombin, actin formed parallel bundles, pMLC co-localized with parallel
actin bundles and VE-cadherin formed a discontinuous band. Arrows denote discontinuous VE-cadherin at the cell margins. FX06 (50 mg/ml)
prevented these thrombin-induced changes; staining patterns were comparable to those seen in control cells or FX06-treated cells. B. The amount
and localization of pMLC, the amount of actin bundling and the continuity of VE-cadherin as exemplified in (A) were quantified in 15 randomly
photographed LSM images derived from 3 independent experiments by 2 observers blinded to the condition as described in Methods. Thrombin
induced a significant raise in scores as compared to controls (p,0.05) and this was significantly reduced by FX06 (p,0.05, median and interquartile
ranges are shown (* denotes the 25% and 75% ranges).
doi:10.1371/journal.pone.0005391.g003
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fields per sample blinded to the conditions.
Lipopolysaccaride pneumonitis. Female 29S7/SvEvBrd*
C57BL/6 wild-type or female 29S7/SvEvBrd*C57BL/6 Fyn
2/2
mice (The Jackson Laboratory) were anesthetized by inhalation of
isoflurane (Abbott Laboratories). LPS (10 mg, E. coli O55:B5;
Sigma-Aldrich) diluted in 50 ml NaCl was instilled intranasally
(i.n.), controls received NaCl only. Then, FX06 (262.4 mg/kg),
random peptide or NaCl were injected i.p., the first dose
immediately after LPS challenge, the second 60 min later.
Figure 4. FX06 reduced thrombin-induced FAK activation. A. Immunofluorescence images (anti-ß-catenin Ab in red, anti-phospho-FAK
(p397FAK) Ab in green). Endothelial cells were treated as indicated for 5 min. Thrombin induced a robust increase in p397FAK and relocation to cell
margins producing a pattern of parallel stripes (arrows) which was not seen in thrombin plus FX06-treated cells. B. The amount and localization of
pFAK as exemplified in (A) was scored in 3 independent experiments by 2 observers blinded to the condition as described in Methods. Thrombin
induced a significant raise in scores as compared to random peptide-treated cells (*p,0.05) and this was significantly reduced by FX06 (p,0.05),
median and interquartile ranges are shown (* denotes the 25% and 75% ranges).
doi:10.1371/journal.pone.0005391.g004
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ketamine (Pfizer) and Evan’s Blue (50 mg/kg; Sigma) was
injected i.v.; 30 min later, mice were sacrificed, lungs were
flushed via the right ventricle using 5 ml cold PBS (pH 7.4),
removed and stored in liquid nitrogen. Frozen lungs were
homogenized in 300 ml PBS at 4uC followed by incubation in
formamide (Calbiochem) at 60uC for 16 h. Absorbance of
supernatants was measured at A620 and A720. Tissue Evan’s Blue
content was corrected for heme pigments (A720) and calculated in
comparison to a standard curve according to the formula:
A620(corrected)=A6202(1.4266A720+0.030).
Immunofluorescence-staining of endothelial cells in
culture
Human Umbilical Vein Endothelial Cells (HUVEC) isolated
from umbilical cords derived from the delivery room of the
Medical University of Vienna, used at passages 2 to 6, were grown
Figure 5. FX06 prevents thrombin-induced RhoA activation. Endothelial cells were exposed to thrombin (1 U/ml), FX06 (50 mg/ml) or
thrombin plus FX06 for indicated times. Pull down experiments were performed with GST-coupled Rhotekin (for activated RhoA) or with GST-coupled
Pak-1 (for activated Rac1). Graphs depict the mean+/2SD of 4 independent experiments. Thrombin induced significant elevations of RhoA and
reductions of Rac1 activity as indicated by asterisks (p,0.05 compared to sham). FX06 alone had the reverse effect (asterisks denote p,0.05
compared to sham). In thrombin plus FX06-treated cells, RhoA activation was completely inhibited (asterisks denote p,0.05 compared to cells
treated with thrombin alone). The Western blot is an example of a pull down experiment 2 minutes after stimulation.
doi:10.1371/journal.pone.0005391.g005
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containing 20% fetal calf serum, ECGS (50 mg/ml, Promocell)
and heparin (5 U/ml) w/o or with FX06 (50 mg/ml), thrombin
(1 U/ml) or thrombin+FX06 for indicated times. Following
fixation in 4% paraformaldehyde, slides were stained with the
following first step antibodies diluted in PBS containing 0.1%
TritonX-100 and 1% bovine serum albumin: rabbit anti-phospho-
myosin regulatory light chain (3 mg/ml; Chemicon Int.), mouse
anti-VE-cadherin (TEA1/31, 1 mg/ml; Immunotech), rabbit-anti-
b-catenin (1 mg/ml; Sigma-Aldrich) and mouse anti-phospho focal
adhesion kinase (pY397, 0.5 mg/ml; BD Transduction Laborato-
ries). Second step Abs were Cy5-labeled goat anti-mouse IgG
(Jackson Laboratories) and Alexa488-labeled anti-rabbit IgG
(Invitrogen-Molecular Probes). To visualize actin, sections were
incubated with TRITC-labeled phalloidin (0.5 mg/ml; Sigma-
Aldrich). Sections were then analyzed by a confocal laser scan
microscope (LSM 510, Zeiss) with a pinhole of one airy unit,
resulting in a section thickness of 0.8 mm.
Evaluation of stress response was performed by 2 independent
observers. Figure 3B shows summation of scores, which were
determined as follows.
– parallel actin bundles; absent=0, discrete bundling=1,
parallel fibers=2
– myosin light chain phosphorylation; only at junction cross
points=0, minimal colocalization with stress fibers=1, strong
colocalization with stress fibers=2
– VE-cadherin membrane staining; continuous=0, single dis-
continuous sites/cell=1 discontinuous staining=2
FAK staining (Fig. 5A) was scored as follows: weak and
cytoplasmic=0, strong and cytoplasmic=1, strong and at tips of
stress fibers=2.
RhoA and Rac1 Pull Down
HUVEC grown to confluence were incubated with FX06
(50 mg/ml), thrombin (1 U/ml) or thrombin+FX06 for indicated
times or were left untreated. Active RhoA was pulled down by
using Rho Assay Reagent (GST-coupled Rhotekin, Upstate) and
active Rac1 by using Rac1/Cdc42 Assay Reagent (GST-coupled
Pak-1, Upstate) according to manufactures instructions. Bound
proteins were separated on a 15% polyacrylamid gel and blotted
on Nitrocellulose-Membrane (Bio-Rad). RhoA was detected with
anti-RhoA antibody (clone55; Upstate). Rac1 was detected with
anti-Rac1 antibody (clone23A8; Upstate). Total RhoA and Rac1
contents were determined in western blots performed from the
same lysates before pull downs were performed.
Immunoprecipitation and Western blotting
HUVEC grown to confluence were stimulated with FX06
(50 mg/ml), thrombin (1 U/ml) or thrombin+FX06 for indicated
times or were left untreated. After washing with PBS (4uC), cells
were scrapped into Tris-lysis buffer containing 1% TritonX-100,
1% NP-40 and a protease and phosphatase inhibitory cocktail
(Sigma-Aldrich). Cells were kept for 20 min on ice and vortexed
every 5 min. Following centrifugation, supernatants were harvest-
ed and added to 50 ml sepharose beads (Sigma-Aldrich), which
were preincubated with the indicated antibodies. Beads were
agitated for 2 h at 4uC, washed and incubated with 26 sample
buffer at 95uC for 5 min. Beads were removed by centrifugation
and supernatants placed onto 10% polyacrylamide gels to separate
precipitated proteins. Following blotting onto PVDF (Bio-Rad)
membranes, washing with TBS/0.5% TWEEN (TBST), blocking
with 1% BSA/TBST for 1 h at RT, membranes were incubated
with the indicated antibodies in 1% BSA/TBST over night at 4uC.
For detection, HRP-labeled goat anti-mouse or anti-rabbit
antibodies (Bio-Rad) in TBST were used and bound Abs were
visualized by chemiluminescence (ECL-system, Amersham Corp.)
and recorded on film.
For Fyn - p190RhoGAP co-precipitation experiments, mem-
brane fractions were isolated by using the Compartmental Protein
Extraction Kit CNMCS (K201301-1-6, Biochain Institute)
according to the manufacturer’s instructions. Protein concentra-
tions were adjusted to 1 mg protein and samples were added to
5 mg anti-p190RhoGAP antibody (Sigma-Aldrich) or 5 mg anti-
Fyn antibody (Santa Cruz) and incubated at 4uC for 12 h. 60 ml
Agarose A beads (preincubated with 5% BSA) were added and
agitated for 12 h at 4uC. Following washing, beads were incubated
with 26sample buffer at 95uC for 5 min. Beads were removed by
Figure 6. FX06 dissociates Fyn from VE-cadherin and associ-
ates Fyn to FAK and p190RhoGAP. Endothelial cells were treated
with thrombin, FX06 or thrombin+FX06 for 1 min. Following lysis,
proteins were immunoprecipitated (IP) and co-precipitated proteins
detected by western blots (WB) as indicated in (A–D). Mean+/2SD of
three independent experiments; *p,0.05 compared to medium
control, **p,0.05 compared to thrombin; representative Western blots
are shown at the right side.
doi:10.1371/journal.pone.0005391.g006
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gels as described above.
Data analysis was done with Dolphin-1D Gel Analysis Software
(Wealtec). Protein bands were identified automatically by the
program and analyzed by comparing the optical densities.
Coprecipitated protein bands were normalized to proteins
precipitated with the respective antibody.
Statistics
T test with Bonferroni’s correction was used. For survival curves
(Fig. 1) we used Kaplan Meier estimates. For figures 3 and 4, non
parametric statistics were used, median and interquartile ranges
are shown and statistics are calculated by Kuskal-Wallis test.
Supporting Information
Figure S1 Knock down of Fyn with lentiviral siRNA smart
vector in cultured HUVEC; Fyn siRNA and control siRNA were
purchased from Dharmacon and used according to the manufac-
turers instructions. For infection 2 MOI/cell were used. Control
staining for Fyn (green) and F-actin (red) in scrambled (A) vs.
specific siRNA infected cells (B). C–F: Cytoskeleton formation
(red) and pFAK (green) distribution in scrambled (C, D) vs. specific
siRNA infected cells (E, F). Cells were treated with 1U Thrombin
(C–F) without FX06 (C, E) and with 50 mg/ml FX06 (D, F) for
1 min.
Found at: doi:10.1371/journal.pone.0005391.s001 (12.04 MB
TIF)
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